New research provides important insights into the process of activation and formation of cells that are crucial for fibrosis to…
Articles by Ana Pena, PhD
Final data from the PRAISE trial support the efficacy and safety of pamrevlumab, an investigational therapy for the treatment…
Surgery is the most effective option to treat lung cancer in people with less severe idiopathic pulmonary fibrosis…
An exploratory Phase 2 study of Prometic‘s investigative oral therapy PBI-4050 in patients…
As many as one in four people with idiopathic pulmonary fibrosis (IPF) may have the illness as a result…
An international group of experts and advocates in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) have…
Promedior‘s investigational therapy for idiopathic pulmonary fibrosis (IPF) — PRM-151 — continues to benefit patients after 76…
Ofev (nintedanib) can prevent…
The New York State Department of Health has authorized the use of Veracyte‘s Envisia Genomic Classifier, the first commercially…
The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have awarded a physician scientist at Northwestern University this…